COMMUNIQUÉS West-GlobeNewswire

Adagene to Participate in Two Upcoming Investor Conferences
12/05/2026
SAN DIEGO and SUZHOU, China, May 12, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today [...]
LiveWorld's New APP Research Council Gives Brands Direct Access to Frontline NP and PA Insights to Improve Relevance, Reach, and ROI
12/05/2026
Targets a long-overlooked gap in pharma marketing: the APP audience driving half of prescribing decisions CAMPBELL, Calif. and NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- LiveWorld, Inc. (OTC Markets: LVWD), a leader in [...]
Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease
12/05/2026
sNDA submission follows agreement with FDA on confirmatory trial, a requirement of the accelerated approval pathway Confirmatory trial designed to demonstrate clinical benefit of mitapivat on reducing transfusion burden [...]
LiveWorld Reports First Quarter 2026 Financial Results
12/05/2026
LiveWorld continues to increase its AI investment CAMPBELL, Calif. and NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- LiveWorld, Inc. (OTC Markets: LVWD), today announced financial results for first quarter 2026. Three [...]
Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2026 Congress
12/05/2026
Oral presentation of data from RALLY-MF phase 2 trial of DISC-0974 in patients with myelofibrosis and anemia Additional abstracts highlighting updates on HELIOS open label extension study of bitopertin in EPP, EPP LIGHT [...]
Ontra Launches AI-Powered DDQ Solution to Accelerate Investor Diligence for Private Markets Firms
12/05/2026
Co-developed with leading private markets firms, Ontra’s solution delivers the speed, accuracy, and consistency investor diligence demands SAN FRANCISCO, May 12, 2026 (GLOBE NEWSWIRE) -- Ontra , the leader in AI-powered [...]
Extendicare Files Business Acquisition Report in connection with the CBI Home Health Acquisition
12/05/2026
MARKHAM, Ontario, May 12, 2026 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) has filed a Business Acquisition Report on Form 51-102F4 (the “BAR”) on SEDAR+ ( www.sedarplus.ca ) in [...]
Ajax Therapeutics Announces Oral Presentation of Clinical Results from AJX-101, a Phase I study of AJ1-11095, a First-in-Class Type II JAK2 Inhibitor, at the European Hematology Society (EHA) 2026 Congress
12/05/2026
– Company unveils first proof-of concept clinical data of AJ1-11095 in patients with myelofibrosis who have been previously treated with a type I JAK2 Inhibitor – NEW YORK and CAMBRIDGE, Mass., May 12, 2026 (GLOBE [...]
Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree
12/05/2026
WARREN, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives [...]
Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress
12/05/2026
– Oral presentation to feature 99-patient dataset with extended follow-up in newly diagnosed NPM1-m or KMT2A-r AML – – High CRc rates (90–96%) with deep MRD negativity (> 80%) across both subtypes – – Durable [...]
NEXGEL To Report First Quarter 2026 Financial Results on May 15th
12/05/2026
Management Will Host a Conference Call at 12:00 P.M. ET on the Same Day LANGHORNE, Pa., May 12, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, [...]
20/20 BioLabs Exclusively Licenses PSA Velocity Algorithm from the University of South Carolina
12/05/2026
Patented Algorithm Designed to Help Identify Otherwise Dangerous Prostate Tumors Earlier Using Repeat Blood Test Results Licensing Agreement Expands 20/20 BioLabs’ AI-Enabled Multi-Cancer Early Detection Platform [...]
Orchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027
12/05/2026
Orchestra BioMed targeting enrollment completion of BACKBEAT Global Pivotal Trial (“BACKBEAT Trial”) by the end of Q3 2026 Orchestra BioMed and Medtronic plc. (NYSE: MDT, “Medtronic”), the Company’s strategic [...]
Evaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 Congress
12/05/2026
Data will reflect the functional characterization of EVX-04 Poster presentation on June 13, 2026 COPENHAGEN, Denmark, May 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing [...]
Four Winners Selected in PerfectServe’s 2026 Nurses of Note Awards Program
12/05/2026
Winners are nurse leaders whose work focuses on mentorship for new nurses, neonatal care and education, and better perioperative care team communication MIAMI, May 12, 2026 (GLOBE NEWSWIRE) -- PerfectServe®, a leading [...]
Independent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline Limits
12/05/2026
Pooled analysis of 90 subjects across 5 trials shows stable mean ejection fraction and no clinically significant left ventricular dysfunction Data demonstrates Annamycin addresses the principal barrier to anthracycline [...]
Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
12/05/2026
Initiated enrollment of Phase 1 Study of PRT12396, mutant-selective JAK2V617F inhibitor in patients with polycythemia vera (PV) and myelofibrosis (MF) The Company expects to file the IND for PRT13722, first-in-class [...]
Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights
12/05/2026
Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026 Lead clinical candidate IND filing in Acumen’s EBD TM ( [...]
Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
12/05/2026
FREDERICK, Md., May 12, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced [...]

Pages